Xin Zhan

Xin Zhan

Auto-generated profile, based on publicly available information

Xin Zhan

Univ Sydney, NHMRC Clin Trials Ctr, Paramatta Rd, Camperdown, NSW 2050, Australia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JGJingli Gao
Jingli Gao
YLYuhao Li
Yuhao Li
YZYijun Zhang
Yijun Zhang
XZXin Zhan
Xin Zhan
XTXue Tian
Xue Tian
SWShouling Wu
Shouling Wu
Background: The association of the severity of hepatic steatosis in metabolic dysfunction–associated fatty liver disease (MAFLD)/metabolic dysfunction–associated steatotic liver disease (MASLD) and the remission of MAFLD/MASLD with CKD occurrence is unclear. Methods and Results: The study enrolled 79 540 participants from the Kailuan cohort. Hepatic steatosis was diagnosed by ultrasound. MAFLD/MASLD was defined as hepatic steatosis combined with metabolic dysfunction and MASLD further excluded alcohol or other causes of liver disease. Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate<60 mL/min per 1.73 m 2 or positive proteinuria (≥1+). Hazard ratio (HR) was calculated by Cox regression models. After a median follow‐up of 12.9 years, CKD occurred in 20 465 participants. After adjusting for potential confounders, MAFLD was associated with a higher risk of CKD compared with non‐MAFLD (HR, 1.12 [95% CI, 1.09–1.16]), and this risk increased with increasing severity of hepatic steatosis ( P ‐trend<0.001). Consistent findings were observed when MASLD was used as the exposure. Compared with persistent non‐MAFLD, no statistical difference was found in the risk of CKD in MAFLD remission (HR, 1.04 [95% CI, 0.95–1.15]); however, MASLD remission still had a higher risk of CKD compared with persistent non‐MASLD (HR, 1.15 [95% CI, 1.03–1.27]). When grouped according to the prior severity of hepatic steatosis, there was no statistically significant difference in risk of CKD in mild‐MAFLD/MASLD remission compared with persistent non‐MAFLD/MASLD, but moderated/severe‐MAFLD/MASLD remission still had a higher risk. Conclusions: The risk of CKD in patients with MAFLD/MASLD increased with the severity of hepatic steatosis. Even after remission of the disease, patients with MAFLD/MASLD with prior moderate to severe hepatic steatosis still had a higher risk of CKD.

30 September 2026 in Journal of the National Cancer Center
Verified
Journal Article
Open access
YLYuhao Li
Yuhao Li
YYYile You
Yile You
DSDequan Shi
Dequan Shi
YLYiqiao Lv
Yiqiao Lv
XZXin Zhan
Xin Zhan
SWShengfeng Wang
Shengfeng Wang

9 October 2024 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ATAnh Dam Tran
Anh Dam Tran
XZXin Zhan
Xin Zhan
AVAnnaëlle Vinzent
Annaëlle Vinzent
LFLorelie Flood
Lorelie Flood
TBTian Bai
Tian Bai
GZGregory S. Zaric
Gregory S. Zaric